Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer (HERMIONE-10)

  • End date
    Mar 20, 2023
  • participants needed
  • sponsor
    University of Milano Bicocca
Updated on 20 April 2022
advanced breast cancer


Multicenter, retrospective and prospective, cohort, observational study evaluating the clinical efficacy and tolerability of Eribulin as second-line treatment in accordance with the indications authorized by AIFA in patients with triple negative advanced breast cancer in a real world setting.


The study, multicenter, retrospective and prospective, cohort, observational, describes the modalities of treatment with Eribulin as a second line therapy for triple negative breast cancer and "clinical outcomes" in a population real-world, evaluating any differences with the results obtained in clinical trials. Therapeutic sequences will also be evaluated with the aim of providing a photograph of the choices made in clinical practice in this historical moment characterized by rapid evolution of new molecules available to clinicians.

A total of at least 200 patients with triple negative advanced breast cancer treated with Eribulin as second line will be enrolled in the retrospective or prospective cohort. Enrollment period will last 2 years.

Pseudoanonymized data will be collected in a electroctronic database (RedCap Cloud); here the list of the main variables collected:

  • Patient Registration
  • Demography
  • Pregnancy test
  • Past history and habits of the patient
  • Previous antineoplastic therapy
  • Anamnesis close to entering the study
  • Vital signs and ECOG performance status (WHO)
  • Blood chemistry tests
  • RECIST 1.1 Baseline and re-evaluations
  • 12 Lead ECG evaluation
  • Eribulin cycles
  • Adverse events
  • Previous and concomitant medications
  • End of study

The retrospective analysis of the choices made in clinical practice and the benefits obtained from the second therapeutic lines could provide important data to favor the definition of prospective randomized studies, and guide the clinician towards a better therapeutic path.

Condition Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer
Clinical Study IdentifierNCT05302778
SponsorUniversity of Milano Bicocca
Last Modified on20 April 2022


Yes No Not Sure

Inclusion Criteria

Performance status according to ECOG equal to 0-2
Locally advanced or triple negative metastatic breast cancer (HR- and HER2-) confirmed histologically
Progressing after first-line chemotherapy for advanced disease
Previous anthracyclines and taxanes therapy (in an adjuvant, neoadjuvant or metastatic), unless the patient is ineligible to receive such treatments
Treatment with Eribulin mesylate since 2017, in accordance with AIFA indications
Adequate haematological, renal and hepatic function, as per clinical practice
Written informed consent

Exclusion Criteria

Breast cancer HER2 + or HR +
Treatment with Eribulin in the context of clinical studies
Patients unsuitable for treatment with Eribulin
Diagnosis of other malignancies in the two years prior to enrollment, with one exception of adequately treated localized basal cell or squamous cell carcinomas of the skin o cervical carcinomas undergoing curative treatment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note